CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lieu, C. H.
Right arrow Articles by Lai, Y. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lieu, C. H.
Right arrow Articles by Lai, Y. K.

Cell Growth & Differentiation, Vol 9, Issue 9 767-776, Copyright © 1998 by American Association of Cancer Research


ARTICLES

Role of mitogen-activated protein kinase in taxol-induced apoptosis in human leukemic U937 cells

CH Lieu, CC Liu, TH Yu, KD Chen, YN Chang and YK Lai
Department of Life Science, National Tsing Hua University, Hsinchu, Taiwan, Republic of China.

The induction of apoptosis by Taxol was investigated in human leukemic U937 cells. Treatment of U937 cells with 20 nM Taxol for 24 h induced apoptosis in 30-40% of cells, which resulted in an 80% growth inhibition 3 days after treatment. Synchronous cells at different cell cycle stages exhibited different sensitivities toward Taxol, and their reversion by certain protein kinase inhibitors was also phase specific. Kinetic studies of cell cycle progress reveal that Taxol accelerates the progression of the cell cycle, which facilitates the process of apoptosis, especially for cells initially in the G1 phase. This acceleration may result from transient activation of p42/ 44 mitogen-activated protein (MAP) kinase, because inhibition of upstream MAP/extracellular signal-regulated kinase kinase (MEK1/2) by PD98059 reversed this effect. However, the delayed S-G2-M-phase progression by PD98059 was insignificant. The results suggest that MAP kinase may not only mediate cell cycle progress but may also participate in the apoptosis pathway for cells originally in S phase.


This article has been cited by other articles:


Home page
J. Lipid Res.Home page
E. S. Jeon, H. Y. Song, M. R. Kim, H. J. Moon, Y. C. Bae, J. S. Jung, and J. H. Kim
Sphingosylphosphorylcholine induces proliferation of human adipose tissue-derived mesenchymal stem cells via activation of JNK
J. Lipid Res., March 1, 2006; 47(3): 653 - 664.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. J. Taxman, J. P. MacKeigan, C. Clements, D. T. Bergstralh, and J. P-Y. Ting
Transcriptional Profiling of Targets for Combination Therapy of Lung Carcinoma with Paclitaxel and Mitogen-activated Protein/Extracellular Signal-regulated Kinase Kinase Inhibitor
Cancer Res., August 15, 2003; 63(16): 5095 - 5104.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. H. Yoo, M. P. Piechocki, J. F. Ensley, T. Nguyen, J. Oliver, H. Meng, D. Kewson, T. Y. Shibuya, F. Lonardo, and M. A. Tainsky
Docetaxel Induced Gene Expression Patterns in Head and Neck Squamous Cell Carcinoma Using cDNA Microarray and PowerBlot
Clin. Cancer Res., December 1, 2002; 8(12): 3910 - 3921.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
H. M. McDaid and S. B. Horwitz
Selective Potentiation of Paclitaxel (Taxol)-Induced Cell Death by Mitogen-Activated Protein Kinase Kinase Inhibition in Human Cancer Cell Lines
Mol. Pharmacol., August 1, 2001; 60(2): 290 - 301.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. Yu, S. Wang, P. Dent, and S. Grant
Sequence-Dependent Potentiation of Paclitaxel-Mediated Apoptosis in Human Leukemia Cells by Inhibitors of the Mitogen-Activated Protein Kinase Kinase/Mitogen-Activated Protein Kinase Pathway
Mol. Pharmacol., July 1, 2001; 60(1): 143 - 154.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
J.-i. Okano and A. K. Rustgi
Paclitaxel Induces Prolonged Activation of the Ras/MEK/ERK Pathway Independently of Activating the Programmed Cell Death Machinery
J. Biol. Chem., June 1, 2001; 276(22): 19555 - 19564.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. Dent and S. Grant
Pharmacologic Interruption of the Mitogen-activated Extracellular-regulated Kinase/Mitogen-activated Protein Kinase Signal Transduction Pathway: Potential Role in PromotingCytotoxic Drug Action
Clin. Cancer Res., April 1, 2001; 7(4): 775 - 783.
[Full Text]


Home page
Cancer Res.Home page
M. V. Blagosklonny, P. C. Bishop, R. Robey, T. Fojo, and S. E. Bates
Loss of Cell Cycle Control Allows Selective Microtubule-active Drug-induced Bcl-2 Phosphorylation and Cytotoxicity in Autonomous Cancer Cells
Cancer Res., July 1, 2000; 60(13): 3425 - 3428.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Cell Physiol.Home page
T. Ohigashi, M. Ueno, S. Nonaka, T. Nakanoma, Y. Furukawa, N. Deguchi, and M. Murai
Tyrosine kinase inhibitors reduce bcl-2 expression and induce apoptosis in androgen-dependent cells
Am J Physiol Cell Physiol, January 1, 2000; 278(1): C66 - C72.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
J.-i. Okano and A. K. Rustgi
Paclitaxel Induces Prolonged Activation of the Ras/MEK/ERK Pathway Independently of Activating the Programmed Cell Death Machinery
J. Biol. Chem., June 1, 2001; 276(22): 19555 - 19564.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1998 by the American Association of Cancer Research.